Janus Henderson Group
FOLD

Janus Henderson Group’s Amicus Therapeutics FOLD Stock Holding History

Janus Henderson Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Buy
1,073,865
+936,294
+681% +$13.4M 0.01% 657
2025
Q4 		$1.96M Sell
137,571
-2,328,450
-94% -$22.9M ﹤0.01% 1347
2025
Q3 		$19.4M Sell
2,466,021
-287,689
-10% -$2.05M 0.01% 630
2025
Q2 		$15.8M Sell
2,753,710
-567,443
-17% -$3.66M 0.01% 622
2025
Q1 		$28M Sell
3,321,153
-73,905
-2% -$684K 0.02% 493
2024
Q4 		$32M Sell
3,395,058
-2,940,177
-46% -$30.6M 0.02% 489
2024
Q3 		$67.7M Sell
6,335,235
-6,896,159
-52% -$75.1M 0.03% 326
2024
Q2 		$131M Sell
13,231,394
-583,120
-4% -$5.99M 0.07% 230
2024
Q1 		$163M Buy
13,814,514
+2,307,385
+20% +$29.5M 0.09% 204
2023
Q4 		$163M Sell
11,507,129
-3,426,892
-23% -$38.9M 0.1% 198
2023
Q3 		$182M Buy
14,934,021
+10,433
+0.1% +$135K 0.12% 182
2023
Q2 		$187M Buy
14,923,588
+1,313,153
+10% +$15.6M 0.12% 177
2023
Q1 		$151M Sell
13,610,435
-84,114
-0.6% -$1.04M 0.1% 195
2022
Q4 		$167M Sell
13,694,549
-15,857,681
-54% -$179M 0.12% 181
2022
Q3 		$309M Buy
29,552,230
+12,772,089
+76% +$142M 0.12% 185
2022
Q2 		$180M Buy
16,780,141
+1,157,528
+7% +$9.53M 0.12% 180
2022
Q1 		$148M Buy
15,622,613
+5,764,732
+58% +$54.1M 0.07% 253
2021
Q4 		$114M Buy
9,857,881
+2,803,673
+40% +$31.2M 0.05% 331
2021
Q3 		$67.4M Buy
7,054,208
+2,065,621
+41% +$21.1M 0.03% 470
2021
Q2 		$48.1M Sell
4,988,587
-3,995,468
-44% -$39M 0.02% 573
2021
Q1 		$88.8M Sell
8,984,055
-2,263,153
-20% -$35M 0.04% 400
2020
Q4 		$260M Sell
11,247,208
-2,859,051
-20% -$58.5M 0.12% 179
2020
Q3 		$199M Buy
14,106,259
+2,312,500
+20% +$33.7M 0.1% 201
2020
Q2 		$178M Buy
11,793,759
+167,835
+1% +$2.05M 0.1% 214
2020
Q1 		$107M Buy
11,625,924
+867,308
+8% +$8.24M 0.07% 269
2019
Q4 		$105M Sell
10,758,616
-187,619
-2% -$1.72M 0.05% 356
2019
Q3 		$87.8M Buy
10,946,235
+73,256
+0.7% +$795K 0.05% 410
2019
Q2 		$136M Sell
10,872,979
-183,163
-2% -$2.32M 0.07% 300
2019
Q1 		$150M Sell
11,056,142
-17,442
-0.2% -$213K 0.08% 277
2018
Q4 		$106M Buy
11,073,584
+2,267,225
+26% +$24.9M 0.07% 327
2018
Q3 		$106M Buy
8,806,359
+627,972
+8% +$8.78M 0.06% 381
2018
Q2 		$128M Sell
8,178,387
-367,952
-4% -$5.56M 0.07% 329
2018
Q1 		$129M Buy
8,546,339
+629,638
+8% +$9.58M 0.08% 310
2017
Q4 		$114M Buy
7,916,701
+482,387
+6% +$6.63M 0.07% 344
2017
Q3 		$112M Buy
7,434,314
+407,304
+6% +$5.39M 0.07% 337
2017
Q2 		$70.8M Buy
+7,027,010
New +$56.5M 0.05% 430

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Janus Henderson Group's FOLD Position: Q1 2026 in Review

Janus Henderson Group increased its Amicus Therapeutics (FOLD) stake by 681% in Q1 2026, buying an estimated $13.4M and bringing the position to 1,073,865 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #657.

Janus Henderson Group first reported a position in FOLD in Q2 2017 and has held it in 36 quarters since. The position peaked at $309M in Q3 2022. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Janus Henderson Group held 1,073,865 shares of Amicus Therapeutics worth $15.5M as of Q1 2026.
  • Janus Henderson Group bought 936,294 Amicus Therapeutics shares in Q1 2026, an estimated $13.4M.
  • Amicus Therapeutics made up 0.01% of Janus Henderson Group's portfolio in Q1 2026, its #657 holding.
  • Janus Henderson Group first reported a position in Amicus Therapeutics in Q2 2017 and has held it in 36 quarters since.
  • Janus Henderson Group's Amicus Therapeutics position peaked at $309M in Q3 2022.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.